HBIO logo

Harvard Bioscience Stock Price

Symbol: NasdaqGM:HBIOMarket Cap: US$19.3mCategory: Pharmaceuticals & Biotech

HBIO Share Price Performance

US$0.44
-2.40 (-84.68%)
85.5% undervalued intrinsic discount
US$3.00
Fair Value
US$0.44
-2.40 (-84.68%)
85.5% undervalued intrinsic discount
US$3.00
Fair Value
Price US$0.44
AnalystConsensusTarget US$3.00

HBIO Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$3.00 85.5% undervalued intrinsic discount

Expanding SoHo, BTX, And Mesh MEA Will Open New Markets

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative

Recent HBIO News & Updates

No updates

Harvard Bioscience, Inc. Key Details

US$91.4m

Revenue

US$39.2m

Cost of Revenue

US$52.2m

Gross Profit

US$110.3m

Other Expenses

-US$58.1m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 11, 2025
Earnings per share (EPS)
-1.31
Gross Margin
57.14%
Net Profit Margin
-63.52%
Debt/Equity Ratio
242.4%

Harvard Bioscience, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About HBIO

Founded
1901
Employees
343
CEO
John Duke
WebsiteView website
www.harvardbioscience.com

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 11.4%
  • 1 Year: 20.5%
  • Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading